Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tifcemalimab by Shanghai Junshi Biosciences for Non-Small Cell Lung Cancer: Likelihood of Approval
Tifcemalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase I for Non-Small Cell Lung Cancer. According...
Tifcemalimab by Shanghai Junshi Biosciences for Small-Cell Lung Cancer: Likelihood of Approval
Tifcemalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase III for Small-Cell Lung Cancer. According to...
Tifcemalimab by Shanghai Junshi Biosciences for Solid Tumor: Likelihood of Approval
Tifcemalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase I for Solid Tumor. According to GlobalData,...
Tifcemalimab by Shanghai Junshi Biosciences for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Tifcemalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)....